Last Price$61.4(0.0%)
Market Cap$7,773.1M
LTM Cash Flow from Operating Activities
$479.1M
YoY Growth
+23.3%
3Y CAGR
+17.0%
5Y CAGR
N/A
Stock quality & Intrinsic value
8/10
10.3% overvalued
Halozyme Therapeutics, Inc. Cash Flow from Operating Activities
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | ($13.0M) | $7,079.6K | ($147.7K) | ($35.4M) | ($40.1M) | ($45.4M) | ($34.4M) | ($64.3M) | ($49.3M) | ($47.5M) | ($37.1M) | ($50.4M) | $134.1M | ($49.5M) | ($85.4M) | $55.5M | $299.4M | $240.1M | $388.6M | $479.1M |
Overvalued or undervalued?
Check the intrinsic value for HALO
and see if it's the right time to invest.
Halozyme Therapeutics, Inc. (HALO) Cash Flow from Operating Activities comparison analysis
General
LTM Cash Flow from Operating Activities
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Halozyme Therapeutics, Inc.HALO
$479.1M
23.3%
17.0%
N/A
Median Peer Set
$108.2M
(1.9%)
(7.3%)
0.0%
Regeneron Pharmaceuticals, Inc.REGN
$4,420.5M
(3.8%)
(14.5%)
12.7%
Royalty Pharma plcRPRX
$2,769.0M
(7.3%)
11.1%
29.2%
United Therapeutics CorporationUTHR
$1,327.1M
35.7%
30.4%
N/A
BioMarin Pharmaceutical Inc.BMRN
$572.8M
259.7%
23.4%
64.0%
BioNTech SEBNTX
$224.7M
(96.1%)
(38.4%)
N/A
Alnylam Pharmaceuticals, Inc.ALNY
($8,312.0K)
N/A
(76.5%)
(50.5%)
Summit Therapeutics Inc.SMMT
($142.0M)
84.9%
25.1%
44.9%
argenx SEARGX
($145.5M)
(76.5%)
(30.4%)
N/A
BeiGene, Ltd.BGNE
($437.4M)
(65.1%)
(27.0%)
(8.4%)
Vertex Pharmaceuticals IncorporatedVRTX
($492.6M)
N/A
N/A
N/A
HALO key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.1 0.0% | 1.0 671.8% | 3.8 287.0% | 8.8 130.7% | 13.7 56.0% | 13.6 (0.3%) | 56.1 311.7% | 42.3 (24.5%) | 54.8 29.5% | 75.3 37.5% | 135.1 79.3% | 146.7 8.6% | 316.6 115.8% | 151.9 (52.0%) | 196.0 29.1% | 267.6 36.5% | 443.3 65.7% | 660.1 48.9% | 829.3 25.6% | 1,015.3 22.4% |
| Cost of Goods Sold (COGS) | 0.1 | 0.4 | 0.2 | 0.3 | 0.3 | 1.0 | 0.3 | 1.1 | 6.2 | 22.7 | 29.2 | 33.2 | 31.2 | 10.1 | 45.5 | 43.4 | 81.4 | 139.3 | 192.4 | 159.4 |
% margin | 0.1 59.1% | 0.5 55.5% | 3.6 93.7% | 8.4 96.2% | 13.4 97.7% | 12.6 92.8% | 55.8 99.5% | 41.2 97.4% | 48.6 88.6% | 52.6 69.8% | 105.8 78.3% | 113.5 77.4% | 285.5 90.2% | 141.7 93.3% | 150.4 76.8% | 224.2 83.8% | 361.9 81.6% | 520.8 78.9% | 636.9 76.8% | 855.9 84.3% |
| Operating Expenses | 13.6 | 16.1 | 31.7 | 58.9 | 71.8 | 66.9 | 75.7 | 94.9 | 129.0 | 115.6 | 133.3 | 196.7 | 204.5 | 211.1 | 218.1 | 80.0 | 86.0 | 253.3 | 299.3 | 304.4 |
| Research & Development Expenses (R&D) | 10.2 | 9.2 | 20.6 | 44.2 | 56.6 | 51.8 | 57.6 | 70.0 | 96.6 | 79.7 | 93.2 | 150.8 | 150.6 | 150.3 | 140.8 | 34.2 | 35.7 | 66.6 | 76.4 | 79.0 |
| Selling, General & Administrative Expenses (SG&A) | 3.4 | 6.9 | 11.2 | 14.6 | 15.2 | 15.1 | 18.1 | 24.8 | 32.3 | 35.9 | 40.0 | 45.9 | 53.8 | 60.8 | 77.3 | 45.7 | 50.3 | 143.5 | 149.2 | 154.3 |
% margin | (13.6) (10,660.7%) | (15.6) (1,587.3%) | (28.2) (740.9%) | (50.4) (575.5%) | (58.5) (427.6%) | (54.3) (398.2%) | (19.8) (35.4%) | (53.6) (126.7%) | (80.4) (146.8%) | (63.0) (83.7%) | (27.5) (20.3%) | (83.2) (56.7%) | 81.0 25.6% | (69.3) (45.7%) | (67.6) (34.5%) | 144.3 53.9% | 275.9 62.2% | 267.5 40.5% | 337.6 40.7% | 551.5 54.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 1.7 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.1 | 15.0 | 6.4 | 15.9 | 0.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.3 | 5.6 | 5.2 | 20.0 | 22.0 | 18.0 | 11.6 | 20.4 | 7.5 | 16.9 | 18.8 | 18.1 |
| Pre-tax Income | (13.3) | 0.0 | 0.0 | (48.7) | (58.4) | (53.2) | (19,769.9) | (53.6) | (83.5) | (68.4) | (32.2) | (101.9) | 61.6 | (79.8) | (72.3) | 129.3 | 248.5 | 248.9 | 348.3 | 557.1 |
% effective tax rate | (0.3) 2.2% | (0.8) 0.0% | (4.3) 0.0% | (0.1) 0.1% | 0.0 0.0% | (1.0) 1.9% | (1.2) 0.0% | (1.1) 2.1% | 2.0 (2.5%) | 3.8 (5.6%) | 3.5 (10.9%) | 1.2 (1.1%) | (1.4) (2.2%) | 0.5 (0.7%) | (0.0) 0.0% | 0.2 0.2% | (154.2) (62.0%) | 46.8 18.8% | 66.7 19.2% | 113.0 20.3% |
% margin | (13.3) (10,435.9%) | (14.8) (1,502.6%) | (23.9) (628.9%) | (48.7) (555.2%) | (58.4) (426.9%) | (53.2) (390.8%) | (19.8) (35.2%) | (53.6) (126.5%) | (83.5) (152.3%) | (68.4) (90.8%) | (32.2) (23.9%) | (103.0) (70.2%) | 63.0 19.9% | (80.3) (52.9%) | (72.2) (36.9%) | 129.1 48.2% | 402.7 90.8% | 202.1 30.6% | 281.6 34.0% | 444.1 43.7% |
| EPS | (0.26) | (0.24) | (0.32) | (0.61) | (0.67) | (0.56) | (0.19) | (0.48) | (0.74) | (0.56) | (0.25) | (0.81) | 0.46 | (0.56) | (0.50) | 0.95 | 2.86 | 1.48 | 2.13 | 3.50 |
| Diluted EPS | (0.26) | (0.24) | (0.32) | (0.61) | (0.67) | (0.56) | (0.19) | (0.48) | (0.74) | (0.56) | (0.25) | (0.81) | 0.45 | (0.56) | (0.50) | 0.91 | 2.74 | 1.44 | 2.10 | 3.43 |
% margin | (13.4) (10,498.5%) | (14.5) (1,477.8%) | (28.2) (740.9%) | (49.4) (563.5%) | (56.9) (416.3%) | (52.7) (387.2%) | (18.7) (33.3%) | (52.5) (124.0%) | (79.0) (144.1%) | (61.0) (81.0%) | (25.4) (18.8%) | (79.5) (54.2%) | 83.2 26.3% | (69.3) (45.7%) | (56.6) (28.9%) | 153.0 57.2% | 259.0 58.4% | 315.5 47.8% | 451.9 54.5% | 656.5 64.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Halozyme Therapeutics, Inc.'s Cash Flow from Operating Activities?
As of today, Halozyme Therapeutics, Inc.'s last 12-month Cash Flow from Operating Activities is $479.1M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Halozyme Therapeutics, Inc.'s Cash Flow from Operating Activities growth rate?
Over the last year, Halozyme Therapeutics, Inc.'s Cash Flow from Operating Activities growth was 23.3%. The average annual Cash Flow from Operating Activities growth rates for Halozyme Therapeutics, Inc. have been 46.6% over the past three years, N/A over the past five years.
3) Is Halozyme Therapeutics, Inc.'s Cash Flow from Operating Activities growth rate Good?
Over the last year, Halozyme Therapeutics, Inc.'s Cash Flow from Operating Activities growth was 23.3%, which is higher than industry growth of (0.0%). It indicates that Halozyme Therapeutics, Inc.'s Cash Flow from Operating Activities growth is Good.